Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 5/20 | 0.47 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.39 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 8/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13125239 | 0.81 | HTR7 (0.44) | P2RX3KCNJ5KCNJ3CA2 | |
| SCHEMBL944361 | 0.81 | P2RX3 (0.41) | P2RX3KCNJ5KCNJ3CA2 | |
| SCHEMBL945863 | 0.81 | P2RX3 (0.41) | P2RX3KCNJ5KCNJ3CA2 | |
| SCHEMBL23374815 | 0.81 | P2RX3 (0.41) | P2RX3KCNJ5KCNJ3CA2 | |
| SCHEMBL13125279 | 0.80 | MRGPRX4 (0.46) | P2RX3KCNJ5KCNJ3 | |
| SCHEMBL12800745 | 0.79 | P2RX3 (0.39) | P2RX3KCNJ5KCNJ3CA2 | |
| SCHEMBL2503804 | 0.77 | CA2 (0.40) | P2RX3KCNJ5KCNJ3CA2 | |
| SCHEMBL2503801 | 0.77 | CA2 (0.40) | P2RX3KCNJ5KCNJ3CA2 | |
| SCHEMBL358068 | 0.76 | MAPK14 (0.42) | P2RX3KCNJ5KCNJ3DRD4CA2 | |
| SCHEMBL12519657 | 0.76 | CA2 (0.42) | P2RX3KCNJ5KCNJ3DRD4CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765764-B2 | 2-acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2014-07-01 | — | — | US | disclosed |
| US-20130079351-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA, INC. (JP) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079351-A1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF | MPL, JAK2, ABL1 | P2RX3 3334/4885KCNJ5 2628/4885KCNJ3 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.